Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Study of Vornorexant (TS-142) in Patients with Insomnia
NCT05461352Phase 3Completed
- Sponsor
- Taisho Pharmaceutical
- Start
- Oct 2022
- Primary completion
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of vornorexant in insomnia disorder, sponsored by Taisho Pharmaceutical. Started Oct 2022; status: completed.
02
Drugs
vornorexant
03
Conditions
insomnia disorder
Beyond the preview
Go deeper on NCT05461352.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05461352.